What's in the pipeline for the treatment of Parkinson's disease?
Parkinson's disease (PD) is a common, debilitating neurodegenerative disorder that creates a significant burden for patients, family members and society at large. Major unmet needs include effective therapies that could favorably modify the underlying pathogenetic processes in PD, and better control of motor and nonmotor symptoms in advanced-stage disease. This review examines the current state of development of potential PD therapies, including dopaminergic therapies, modulators of adenosine and glutamate receptors, cell-based therapies, genetic therapies and device-based therapies. In addition, research into potential neuroprotective agents and pipeline therapies for nonmotor symptoms of PD are summarized.
Sommer
David B
DB
Movement Disorders Center, Duke University Medical Center, DUMC Box 3333, Durham, NC 27710, USA. david.sommer@duke.edu
Stacy
Mark A
MA
D000978:Antiparkinson Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D018696:Neuroprotective Agents / Q000627:therapeutic use; D010300:Parkinson Disease / Q000628:therapy*
D000978:Antiparkinson Agents; D018696:Neuroprotective Agents